Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
7
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis